Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Conatus Pharmaceuticals
Biotech
After NASH flops, Conatus becomes Histogen via reverse merger
After its NASH drug failed a third midphase trial, Conatus has found its lifeline—a reverse merger with regenerative medicine player Histogen.
Amirah Al Idrus
Jan 29, 2020 10:05am
Conatus wields ax as Novartis-partnered NASH drug fails again
Jun 25, 2019 8:37am
Conatus and Novartis suffer another midphase NASH flop
Mar 22, 2019 9:48am
Midphase failure of Novartis’ NASH drug crushes Conatus
Dec 6, 2018 8:34am
Conatus shares fall on phase 2 data for NASH drug emricasan
Apr 5, 2018 9:49am
Novartis activates license for Conatus' NASH drug emricasan
May 4, 2017 8:37am
